The “Red Alert” That Wasn’t: Deconstructing the 2025 Data Spike
In 2025, the National Poison Data System recorded a record-high 3,434 reports related to kratom alkaloids. While the Global Kratom Coalition (GKC) press release utilized visual alarmism—deploying a red-colored chart to manufacture a sense of urgency—an investigative look at the timeline reveals this “spike” is a classic reporting artifact.
This surge in calls coincides precisely with the FDA’s July 2025 “Dear Colleague” letter and the resulting national media amplification. Administrative alerts and high-profile federal warnings are well known to trigger reporting cascades, where clinicians and the public begin documenting exposures that previously went unreported.
This is not a signal of changing toxicity. It is a signal of changing awareness.
Critically, even after the introduction of bioidentical kratom-derived 7-OH products to the marketplace, kratom-related exposure calls represent approximately 0.06% of all U.S. poison control center calls. Commonplace OTC painkiller acetaminophen accounts for 3% of all poison control center calls, a rate that is 40-50x higher, and accounts for 500 deaths per year. In other words, despite heightened attention, kratom remains an extremely small fraction of national toxicology burden.
We are not observing a toxicological crisis. We are observing regulatory noise being misinterpreted as pharmacological danger.
Exposure Calls ≄ Danger Signals: What the Numbers Actually Say
Data from the 2026 Morbidity and Mortality Report (MMWR) provides essential context. Single-substance reports account for approximately 62% of all kratom cases and are associated with relatively low hospitalization rates (24%–29%). In contrast, multi-substance exposures drive the majority of severe outcomes, with hospitalization rates reaching 56% and serious outcomes occurring in 66% of these cases.
Mortality data follows the same pattern. Of 233 reported deaths, 184 involved multiple substances, demonstrating that outcomes are overwhelmingly driven by polydrug toxicity rather than kratom or 7-OH in isolation.
This distribution highlights an important clinical and public health consideration: the need for improved education around potential drug-drug interactions involving kratom and 7-OH, particularly in the context of polysubstance use. However, these data do not indicate a broader epidemiologic trend of overdose mortality driven by kratom or 7-OH alone.
This interpretation is consistent with federal mortality surveillance. According to the CDC’s State Unintentional Drug Overdose Reporting System (SUDORS) database, kratom-positive overdose deaths account for only ~2% of all overdose deaths over the past five years, and in the vast majority of these cases, fentanyl is present.
Taken together, these findings indicate that kratom is not a population-level driver of overdose mortality and remains substantially underrepresented relative to its prevalence of use.
The 7-OH Safety Profile: Structurally Distinct and Scientifically Safer
Understanding pharmacology is essential to interpreting epidemiology.
7-hydroxymitragynine (7-OH) is a G protein-biased partial mu-opioid receptor agonist with limited intrinsic efficacy. It preferentially activates analgesic signaling pathways while minimizing recruitment of beta-arrestin pathways associated with respiratory depression.
This mechanistic profile is consistent with a ceiling effect on respiratory suppression, distinguishing it from full opioid agonists such as fentanyl, oxycodone, and morphine.
Real-world data reflect this distinction. There are no confirmed deaths attributable to 7-OH alone, despite an estimated consumer base exceeding 1 million individuals.
This is not consistent with the profile of a substance driving a “fourth wave” of overdose deaths.
Displacement and Harm Reduction: 7-OH as a Life-Saving Alternative
Since 2023, U.S. overdose deaths have begun to decline for the first time in years. While expanded naloxone access has contributed, it does not fully explain the magnitude of the trend. Additional factors, such as the introduction of 7-OH products to the market, may have contributed.
7-OH is acting as a viable, non-lethal substitute for users who are actively seeking to avoid the deadly illicit fentanyl market. The human element of the data confirms this displacement. For many, 7-OH is not a “drug of abuse” but a literal lifeline that keeps them away from street-level synthetics.
Consumer-reported outcomes reinforce this interpretation:
“Kratom has saved my life. I was an IV heroin and fentanyl user for a decade. 7-OH and kratom keeps me off the streets. After I got clean, everyone I was using with died. I would have been right there with them. I owe my life to kratom” — Caitlin, NC
“7-OH helped me come off heroin & fentanyl and other opiates. I’m scared people will go back to street drugs if this becomes illegal.” — Zac, AZ
“Without these compounds I’d probably still have a needle in my arm or be dead! Instead I have a successful family. I own a home and I have hope!” — Kye, OH
While anecdotal, these narratives are consistent with a displacement effect rather than an emerging crisis.
Standardized Access vs. Illicit Threats
The policy question is not whether risk exists. All psychoactive substances carry risk.
The question is comparative risk.
Regulated 7-OH products manufactured under GMP conditions offer standardized dosing, labeling, and third-party testing. In contrast, illicit fentanyl markets remain characterized by extreme unpredictability, with DEA data indicating that over 40% of samples contain potentially lethal doses.
Many of these products are further adulterated with compounds such as xylazine, nitazenes, or cychlorphine, compounding respiratory and cardiovascular risk.
Eliminating regulated alternatives based on misinterpreted poison center data would not reduce harm. It would shift consumers toward a demonstrably more dangerous supply.
The policy debate must choose between regulated transparency and illicit chaos.
Conclusion: The Real Cost of Misinformation
The 2025 increase in poison center calls reflects a reporting artifact driven by federal communication and media amplification – not a change in pharmacological risk.
When contextualized:
- Kratom exposure calls represent ~0.06% of poison center volume.
- Kratom-positive deaths represent ~2% of overdose fatalities, and over 70% are also positive for fentanyl.
- No confirmed deaths from 7-OH alone have been identified.
These are not signals of a public health emergency. They are signals of misinterpretation.
The data points to a possibility that 7-OH may be contributing to harm reduction in a landscape dominated by fentanyl. Mischaracterizing this signal risks removing a safer alternative and exacerbating the very crisis policymakers aim to solve.
If a substance is associated with widespread use, minimal standalone mortality, and a profile suggestive of lower risk relative to illicit opioids, the relevant policy question is not whether it should be categorically banned, but how it should be appropriately regulated and studied.
A critical final question remains: who benefits from a narrative that frames lower-risk alternatives as public health threats?
